NZ Lymphoma / Leukaemia Research Review Issue 39

In this issue:

Clonal haematopoiesis increases atherosclerosis risk
Azithromycin worsens airflow decline-free survival after allogeneic SCT
Leukaemia selection
Midostaurin + chemotherapy for FLT3-mutated AML
Ibrutinib vs. standard care in relapsed/refractory CLL
Pembrolizumab in CLL/ Richter’s transformation
Comorbidities at diagnosis and survival in CLL

Lymphoma selection
Long-term follow-up of contemporary treatment in early-stage HL
Pembrolizumab for relapsed/ refractory classic HL
Subsequent primary malignancies after DLBCL in the rituximab era
Double-hit lymphoma outcomes after first CR

Please login below to download this issue (PDF)